Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,097 result(s) found for: Blood disorder. Displaying page 1 of 105.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000685-29 Sponsor Protocol Number: B4Z-KL-LYEC Start Date*: 2021-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3b, Randomized, Open-Label Assessment of Response to Various Doses of Atomoxetine Hydrochloride in Korean Pediatric Outpatients With Attention-Deficit/Hyperactivity Disorder
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002221-21 Sponsor Protocol Number: SPD503-312 Start Date*: 2011-08-30
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Randomized, Multi-center, Placebo controlled, Dose-optimization Study Evaluating the Safety, Efficacy, and Tolerability of Once daily Dosing with Extended-release Guanfacin...
    Medical condition: Attention-Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10037175 - Psychiatric disorders 10068451 ADHD, combined type LLT
    14.0 10037175 - Psychiatric disorders 10068453 ADHD, predominantly inattentive type LLT
    14.0 10037175 - Psychiatric disorders 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.0 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2022-003237-19 Sponsor Protocol Number: 82695 Start Date*: 2023-04-03
    Sponsor Name:Amsterdam UMC
    Full Title: The difference in pharmacodynamic and pharmacokinetic profiles between Tentin and generic dexamphetamine in adults with attention deficit hyperactivity disorder, a double-blinded randomized crossov...
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10064104 ADHD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-018161-12 Sponsor Protocol Number: SPD503-315 Start Date*: 2010-12-23
    Sponsor Name:Shire Development Inc
    Full Title: A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...
    Medical condition: Attention-Deficit/Hyperactive Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004873 10068451 ADHD, combined type LLT
    14.1 100000004873 10068453 ADHD, predominantly inattentive type LLT
    14.1 100000004873 10068452 ADHD, predominantly hyperactive-impulsive type LLT
    14.1 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) ES (Completed) SE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000034-42 Sponsor Protocol Number: 2022-001 Start Date*: 2022-04-22
    Sponsor Name:Aarhus University Hospital - Psychiatry, Department of Affective Disorders
    Full Title: The Estimated 12-Hour Serum Lithium Level Pilot Study
    Medical condition: Bipolar disorder Unipolar Depression
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10004938 Bipolar disorders HLT
    21.1 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-004425-42 Sponsor Protocol Number: CHDR0723 Start Date*: 2008-09-15
    Sponsor Name:Centre for Human Drug Research
    Full Title: Neurocognitive testing in children with ADHD
    Medical condition: Attention Deficit Hyperactivity Disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002111-82 Sponsor Protocol Number: 42603ATT3013 Start Date*: 2007-10-24
    Sponsor Name:Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...
    Medical condition: Attention Deficit-Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003735 Attention deficit-hyperactivity disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) SE (Completed) NL (Completed) DK (Completed) FI (Completed) BE (Completed) GB (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-003845-41 Sponsor Protocol Number: UCL/07/131 Start Date*: 2009-02-06
    Sponsor Name:University College London
    Full Title: Transplantation of umbilical cord blood (UCB) from unrelated donors (URD) in patients with haematological diseases using a reduced intensity conditioning regimen.
    Medical condition: Haematological disorders
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019930-28 Sponsor Protocol Number: 31116 Start Date*: 2011-03-09
    Sponsor Name:Accare
    Full Title: The effectiveness of Parent-Child Interaction Therapy versus methylphenidate in preschool children with ADHD and disruptive behavior problems with insufficient improvement through Parent Management...
    Medical condition: ADHD ODD
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064104 ADHD LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000320-18 Sponsor Protocol Number: FASE01 Start Date*: 2012-11-22
    Sponsor Name:Parnassia Bavo Groep - PsyQ
    Full Title: Phase shift in adult ADHD of sleep and apetite.
    Medical condition: Delayed Sleep Phase Syndrome (DSPS) in adult patients with Attention-Deficit/Hyperctivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10064104 ADHD LLT
    16.1 10029205 - Nervous system disorders 10012209 Delayed sleep phase PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-010982-22 Sponsor Protocol Number: DSC/08/2357/38 Start Date*: 2009-04-20
    Sponsor Name:ITALFARMACO
    Full Title: Phase II study of the histone-deacetylase inhibitor GIVINOSTAT (ITF2357) in combination with hydroxyurea in patients with JAK2V617F positive Polycythemia Vera non-responder to hydroxyurea monotherapy
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004851 10018847 Haematological disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-020951-30 Sponsor Protocol Number: SPD489-404 Start Date*: 2011-03-03
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
    Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed) BE (Completed) ES (Completed) SE (Completed) PL (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000465-31 Sponsor Protocol Number: CannaBiD Start Date*: 2016-06-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Cannabidiol in Bipolar Depression – CannaBiD-Study: An 8-week randomized, double-blind, placebo-controlled clinical trial of Cannabidiol as add-on therapy in bipolar depression
    Medical condition: Bipolar disorder, current episode depressed
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10004936 Bipolar depression LLT
    19.0 10037175 - Psychiatric disorders 10057667 Bipolar disorder PT
    19.0 10037175 - Psychiatric disorders 10026756 Manic depressive illness LLT
    19.0 10037175 - Psychiatric disorders 10026755 Manic depressive LLT
    19.0 10037175 - Psychiatric disorders 10004911 Bipolar affective disorder, depressed LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005452-34 Sponsor Protocol Number: SPD489-406 Start Date*: 2013-08-20
    Sponsor Name:Shire Development LLC
    Full Title: A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, ...
    Medical condition: Attention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivity
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004873 10064104 ADHD LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000679-90 Sponsor Protocol Number: SPD489-325 Start Date*: 2009-04-08
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Randomised, Double-Blind, Multicentre, Parallel-Group, Placebo- and Active-Controlled, Dose-Optimisation Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and ...
    Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FR (Completed) ES (Completed) NL (Completed) SE (Completed) BE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-018086-12 Sponsor Protocol Number: BI1412_2009 Start Date*: 2010-08-23
    Sponsor Name:Athena Care/ Isala Klinieken
    Full Title: Efficacy and safety of Haemocomplettan® P in patients experiencing microvascular bleeding while undergoing elective complex cardiac surgery
    Medical condition: Elective complex cardiac surgery is associated with excessive blood loss due to coagulopathy. Fibrinogen concentrate has been shown to reverse dilutional coagulopathy. In this double blinded, place...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009802 Coagulopathy LLT
    12.1 10000531 Acquired afibrinogenaemia LLT
    12.1 10005517 Blood fibrinogen LLT
    12.1 10011976 Decreased plasma fibrinogen LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004444-19 Sponsor Protocol Number: CRIT124D2201 Start Date*: 2016-04-05
    Sponsor Name:Novartis Pharmaceutical corporation
    Full Title: An open-label, behavioral-treatment-controlled evaluation of the effects of extended release methylphenidate (Ritalin® LA) on the frequency of cytogenetic abnormalities in children 6 - 12 years of ...
    Medical condition: To determine whether the administration of extended-release methylphenidate in treatment-naïve children with ADHD affects the frequency of chromosomal abnormalities.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10037175 - Psychiatric disorders 10003736 Attention deficit/hyperactivity disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-004668-31 Sponsor Protocol Number: SPD503-318 Start Date*: 2012-03-14
    Sponsor Name:Shire Pharmaceutical Development Ltd
    Full Title: A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...
    Medical condition: Attention Deficit/Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004873 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) AT (Completed) ES (Completed) IE (Completed) BE (Completed) IT (Completed) NL (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000720-10 Sponsor Protocol Number: SPD489-326 Start Date*: 2008-11-20
    Sponsor Name:Shire Pharmaceutical Development Limited
    Full Title: A Phase III, Double- Blind, Placebo- Controlled, Randomised Withdrawal, Multicentre, Extension, Safety and Efficacy of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17 with A...
    Medical condition: Attention Deficit / Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10064104 ADHD LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) SE (Completed) BE (Completed) GB (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-001872-54 Sponsor Protocol Number: ARC1779−006 Start Date*: 2009-01-24
    Sponsor Name:Archemix Corp
    Full Title: A Randomized, Double−blind, Placebo−controlled, Clinical Outcome Study of ARC1779 Injection in Patients with Thrombotic Microangiopathy.
    Medical condition: Thrombotic microangiopathy (TMA) disorders
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009731 Coagulation disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 04:55:07 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA